No easy home runs: early Long COVID Paxlovid and monoclonal trials
- Condition
- Long COVID
- At worst
- Not stated
- Ill for
- Not stated
- Published
- Aug 2025
Summary
Amy Engebretson took part in Yale's PaxLC trial of Paxlovid and has continued taking ritonavir, one of Paxlovid's components, because she says it "improved my symptoms quite a bit"; the article gives no specific dose or treatment duration for her. It does not state how long she had been ill or how severe her Long COVID was before treatment, nor does it quantify how much better she got. She is still taking the drug on an ongoing basis, but the article gives no information on whether the benefit has held steady, faded, or required dose changes.
What they credit
Credits Paxlovid, Biologics & antibodies, Monoclonal antibodies (casirivimab, Pemgarda), Paxlovid / nirmatrelvir.
Similar stories
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Monoclonal antibodies article comments
Credits monoclonal antibody. An unnamed patient was ill 4.5y with severe long COVID, improved, then relapsed. Pemgarda gives 8-10 week remission per dose.
-
Three Long-term Long COVID Patients, Three Rapid Recoveries
Pemivibart (Pemgarda), a monoclonal antibody infusion whose effect the article says typically lasts about a couple of months, was given to three long-term long COVID patients. A 70-year-old woman, sick for nearly a year, had her brain fog, breathlessness and…
-
Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 3)
The third patient, who had type II diabetes and was overweight, was severely ill with long COVID for about five months. After receiving the casirivimab and imdevimab cocktail the post reports his symptoms disappeared within a week. He was reportedly…